Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs

 
• By Mandy Jackson
  
T-cells attacking cancer_1200x675
Amgen's BiTE molecules recruit T-cells to targeted tumors. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category